Overview

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

Status:
Active, not recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
to Compare the Pharmacokinetics and Safety of BAT3306 versus KEYTRUDA® Administered in Healthy Male Subjects
Phase:
Phase 1
Details
Lead Sponsor:
Bio-Thera Solutions
Collaborator:
Wuhan Union Hospital, China
Treatments:
Antibodies
Antibodies, Monoclonal
Pembrolizumab